New hormone targets same brain region as GLP-1 drugs to fight obesity
Fox News • • health
Key Points:
- Researchers at the University of Oklahoma discovered a hormone called FGF21 that may reverse obesity by signaling a brain region involved in metabolism and appetite, similar to GLP-1 drugs.
- FGF21 acts by increasing metabolic rate and energy burning, differing from GLP-1 which reduces food intake through appetite suppression.
- The hormone is also being explored for treating metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease, with hopes for targeted therapies that minimize side effects like gastrointestinal issues and bone loss.
- Experts caution that FGF21 behaves differently in humans than in mice, with early human trials showing only modest weight loss and concerns about potential side effects and long-term tolerance.
- Further research and safety trials, including bone density monitoring, are needed before FGF21-based treatments can be clinically adopted for obesity and related metabolic conditions.
